European Access Academy

A multi-stakeholder initiative aiming to facilitate and support the development of a joint European value framework for the assessment of innovative health technologies

The European Access Academy (EAA) aims to identify key challenges and provide sound input for the implementation of the EU HTA Regulation to help achieve the EC’s mission of improving patient access to life saving innovative technologies.


The EAA Faculty is a member of the European Commission's  HTA Stakeholder Network.


New manuscript just published:


The EAA's fourth publication, on the outcomes of discussions on stakeholder involvement at the EAA Fall Convention 2022, is now available:



Click HERE for details on all of the EAA's publications and convention proceedings.


The EAA Spring Convention 2024


'EU HTA - Finding the Right Balance'


at Erasmus University Rotterdam, The Netherlands

on April 18 / 19, 2024


CLick HERE for details


Register HERE for the virtual Public Session


EAA News & Media Posts



Feb 19, 2024: EAA Post on Uncertainty


Uncertainty: Friend or Foe


The EAA was approached to present on Feb 15th to the Oncology Group of the German Trade Association LAWG its perspective on 'uncertainty'. Four key elements were highlighted (presentation available HERE):


A humanistic perspective on 'uncertainty':

Uncertainty is an essential element of all our lives and cannot be avoided. While events that occurred in the past cannot be changed, a key characteristic of the future is change and related uncertainty. How we approach and manage uncertainty largely impacts our success as individuals and that of society in the future.


A Health Technology Assessment (HTA) perspective on 'uncertainty':

As stipulated by the EU HTA Regulation HTA is able to contribute to the promotion of innovation, which offers the best outcomes for patients and society as a whole.’ Thus, the related risk is twofold:

  1. promoting innovation that does not offer best outcomes and
  2. not promoting innovation that does offer best outcomes.

In line with the EU HTA Regulation, HTA is tasked with finding the right balance across those two types of risks and e.g., discriminate between preventable vs unpreventable uncertainty (Hogervorst et al. 2023).


The quest for certainty and the three pillars of Evidence-based Medicine (EbM):

EbM is our means to reduce uncertainty in medicine. It is based on a triade of information: i) data; ii) clinicians’ perspective; iii) patients’ perspective. In the early phase of developing innovative health technologies only limited experience prevails on the side of clinicians and patients. However, in order to equally represent all three pillars of the EbM triade – based on the available data at a given time point - the EAA strongly advocates for an inclusive societal dialogue to be included alongside each of the upcoming EU HTA assessment reports.


The opportunity of European leadership:

With the EU HTA Regulation being applied from Jan 12th, 2025, these joint EU procedures will create the most impactful HTA globally. No other global market has introduced an HTA process reaching out to 27 member states. A balanced approach to uncertainty will be required to turn this opportunity for leadership by the EU Health Union into a success.


Download the full Statement

Feb 06, 2024: EAA Post regarding 'Roadblocks' for EU HTA


Jan 15, 2024: EAA Post regarding the EU HTA Implementing Acts


Thank you for joining the EAA Fall Convention 2023


'Haemato- / Oncology - A Pace Maker for EU HTA'


at AQuAS, Barcelona, Spain.

We had excellent, lively, controversial and very fruitful and constructive discusssions with our expert panel (including

Caroline Pothet, Roisin Adams, Elisabeth de Vries, Martin Kaiser, César Hernández, Bernhard Wörmann, Brian Cuffel, Eleni Pitta, Marcus Guardian and our co-host Oriol Solà-Morales), and all our participants.


Many thanks to all who contributed!


We look forward to continuing the dialogue and talking about the right balance at the EAA Spring Convention 2024 at Erasmus University Rotterdam (April 18/19).


Now available:


EAA Convention Proceedings Issue #4


(click image to download the pdf)



The EAA is an initiative hosted by Copenhagen University, Utrecht University, Vlerick Business School, Agència de Qualitat I Avaluació Sanitàries de Catalunya, Erasmus University and endorsed & funded by:

Springer Healthcare, Abbvie, AstraZeneca, Bayer, Novartis, Pfizer, Roche, Sanofi , vfa, leem and efpia.

Share by: